The genetic foundation of pure antibody titers of younger wholesome pigs and relationships with illness resilience
Background: Sickness resilience is the flexibleness to maintain up effectivity beneath pathogen publicity nonetheless is troublesome to select for because of breeding populations are raised beneath extreme effectively being. Selection for resilience requires a trait that is heritable, simple to measure on healthful animals, and genetically correlated with resilience. Pure antibodies (NAb) are important parts of the innate immune system and are found to be heritable and associated to sickness susceptibility in dairy cattle and poultry. Our aim was to investigate NAb and complete IgG in blood of healthful, youthful pigs as potential indicator traits for sickness resilience.
Outcomes: Info have been from Yorkshire x Landrace pigs, with IgG and IgM NAb (Four antigens) and complete IgG measured by ELISA in blood plasma collected ~ 1 week after weaning, earlier to their publicity to a pure polymicrobial downside. Heritability estimates have been lower for IgG NAb (0.12 to 0.24, + 0.05) and for complete IgG (0.19 + 0.05) than for IgM NAb (0.33 to 0.53, + 0.07) nonetheless maternal outcomes have been greater for IgG NAb (0.41 to 0.52, + 0.03) and for complete IgG (0.19 + 0.05) than for IgM NAb (0.00 to 0.10, + 0.04).
Phenotypically, IgM NAb titers have been fairly correlated with each other (frequent 0.60), as have been IgG NAb titers (frequent 0.42), nonetheless correlations between IgM and IgG NAb titers have been weak (frequent 0.09). Phenotypic correlations of complete IgG have been affordable with NAb IgG (frequent 0.46) nonetheless weak with NAb IgM (frequent 0.01).
Estimates of genetic correlations amongst NAb confirmed associated patterns nonetheless with small SE, with estimates averaging 0.76 amongst IgG NAb, 0.63 amongst IgM NAb, 0.17 between IgG and IgM NAb, 0.64 between complete IgG and IgG NAb, and 0.13 between complete IgG and IgM NAb. Phenotypically, pigs that survived had barely elevated ranges of NAb and complete IgG than pigs that died. Genetically, elevated ranges of NAb tended to be associated to higher sickness resilience based totally on lower mortality and fewer parenteral antibiotic therapies. Genome-wide affiliation analyses for NAb titers acknowledged a variety of genomic areas, with a variety of candidate genes for immune response.
Conclusions: Ranges of NAb in blood of healthful youthful piglets are heritable and potential genetic indicators of resilience to polymicrobial sickness.
geno-type
 Nelociguat |
|
MBS3845033-5x100mg |
MyBiosource |
5x100mg |
EUR 5405 |
) Ripa lysate (strong) |
|
E1WP106 |
EnoGene |
50ML |
EUR 60 |
) RIPA Lysis Buffer (Strong) |
|
abx090624-100l |
Abbexa |
100 µl |
EUR 150 |
RIPA Lysis Buffer (Strong) |
|
abx090624-100ml |
Abbexa |
100 ml |
EUR 260.4 |
|
|
RIPA Lysis Buffer (Strong) |
|
abx090624-1ml |
Abbexa |
1 ml |
Ask for price |
RIPA Lysis Buffer (Strong) |
|
abx090624-200l |
Abbexa |
200 µl |
Ask for price |
RIPA Lysis Buffer (Strong) |
|
MBS355478-100mL |
MyBiosource |
100mL |
EUR 210 |
RIPA Lysis Buffer (Strong) |
|
MBS355478-5x100mL |
MyBiosource |
5x100mL |
EUR 640 |
) Carbol Fuchsin (ZN,Strong) |
|
S005-125ML |
EWC Diagnostics |
1 unit |
EUR 3.16 |
|
Description: Carbol Fuchsin (ZN,Strong) |
Carbol Fuchsin (ZN,Strong) |
|
S005-500ML |
EWC Diagnostics |
1 unit |
EUR 10.92 |
|
Description: Carbol Fuchsin (ZN,Strong) |
) Clear Seal Strong Sheet (100) |
|
MAAB-0685 |
Westburg |
each |
EUR 255.61 |
) HiDecal (Strong decalcifying solution) |
|
R085-500ML |
EWC Diagnostics |
1 unit |
EUR 21.95 |
|
Description: HiDecal (Strong decalcifying solution) |
) Tissue/cell lysis buffer（Strong) |
|
RM17482 |
Abclonal |
10mL |
EUR 53.14 |
 Medium) Modified Duncan Strong (DS) Medium |
|
M1237-500G |
EWC Diagnostics |
1 unit |
EUR 80.55 |
|
Description: Modified Duncan Strong (DS) Medium |
 HiVeg Medium) Modified Duncan Strong (DS) HiVeg Medium |
|
MV1237-500G |
EWC Diagnostics |
1 unit |
EUR 80.55 |
|
Description: Modified Duncan Strong (DS) HiVeg Medium |
) anti PAI-1 (very strong for human) |
|
MBS480230-1mg |
MyBiosource |
1mg |
EUR 790 |
anti PAI-1 (very strong for human) |
|
MBS480230-5x1mg |
MyBiosource |
5x1mg |
EUR 3315 |
) Silver Protein for Histology, Strong (not certified) |
|
25108-25 |
Polysciences Europe GmbH |
25g |
EUR 479.52 |
|
Description: 9015-51-4 |
Silver Protein for Histology, Strong (not certified) |
|
25108-5 |
Polysciences Europe GmbH |
5g |
EUR 125.28 |
|
Description: 9015-51-4 |
 Magnetic Base Support Z w/ Strong Magnet - 34.5mm |
|
M-R-1013161 |
MiTeGen |
1 UNIT |
EUR 46 |
|
Description: Magnetic Base Support Z w/ Strong Magnet - 34.5mm |
 Magnetic Base Support Z w/ Strong Magnet - 27.5mm |
|
M-R-1015229 |
MiTeGen |
1 UNIT |
EUR 46 |
|
Description: Magnetic Base Support Z w/ Strong Magnet - 27.5mm |
 Seralite SRA-400, Strong Basic Anion Exchange Resin |
|
52228 |
Sisco Laboratories |
500 Gms |
EUR 5.82 |
|
|
|
Description: Part A |
 Seralite SRC-120, Strong Acid Cation Exchange Resin |
|
14891 |
Sisco Laboratories |
500 Gms |
EUR 3.76 |
|
|
|
Description: Part A |
 A510, Type 2 Macroporous Strong Base Rsin, Chloride Form |
|
50223-1 |
Polysciences Europe GmbH |
1000ml |
EUR 160.92 |
|
Description: 69011-15-0 |
 DiagAg™ Strong Anion Exchange Agarose Particles, 40 μm |
|
DAG-CL23-08 |
Creative Diagnostics |
25 mL |
EUR 920 |
 A510, Type 2 Macroporous Strong Base Resin, Chloride Form |
|
50223-250 |
Polysciences Europe GmbH |
250ml |
EUR 52.92 |
|
Description: 69011-15-0 |
 A400, Type 1 Porous Strong Base Anion Resin, Chorlide Form |
|
50218-1 |
Polysciences Europe GmbH |
1000ml |
EUR 160.92 |
|
Description: 9052-45-3 |
A400, Type 1 Porous Strong Base Anion Resin, Chorlide Form |
|
50218-250 |
Polysciences Europe GmbH |
250ml |
EUR 52.92 |
|
Description: 9052-45-3 |
 Optically clear sealing film for qPCR, Strong Bond, for PP plates, 100/pk |
|
MS1000-PCR2 |
Benchmark Scientific |
1 each |
EUR 149.35 |
 DiagAg™ Phenyl Agarose Strong Hydrophobic Medium, 6% Crosslinked, 24-45 µm |
|
DAG-YS23-27 |
Creative Diagnostics |
25 mL |
EUR 680 |
 DiagAg™ Phenyl Agarose Strong Hydrophobic Medium, 6% Crosslinked, 45-165 µm, Low Capacity |
|
DAG-YS23-28 |
Creative Diagnostics |
25 mL |
EUR 680 |
 DiagAg™ Phenyl Agarose Strong Hydrophobic Medium, 6% Crosslinked, 45-165 µm, High Capacity |
|
DAG-YS23-29 |
Creative Diagnostics |
25 mL |
EUR 680 |
 and DMSO, for PP plates, 100/pk) Foil seals, strong bonding for cold storage (-200 to 110°C) and DMSO, for PP plates, 100/pk |
|
MS1000-F2 |
Benchmark Scientific |
1 each |
EUR 149.35 |
 IHC control with strong, moderate, low/negative expressersHumanBreastBreastIHC control) Estrogen receptor (ER) IHC control with strong, moderate, low/negative expressersHumanBreastBreastIHC control |
|
ERC083 |
Pantomics |
1.5mm |
EUR 50 |
 Strongyloides ELISA Kit |
|
MBS495518-5x96Tests |
MyBiosource |
5x96Tests |
EUR 2380 |
Strongyloides ELISA Kit |
|
MBS495518-96Tests |
MyBiosource |
96Tests |
EUR 520 |
 (HRP)) Strongzyme Goat anti Mouse IgG (H+L) (HRP) |
|
43R-1653 |
Fitzgerald |
1 ml |
EUR 763.2 |
|
Description: Strongzyme Goat anti-Mouse IgG (H+L) secondary antibody (HRP) |
 (HRP)) Strongzyme Rabbit anti Goat IgG (H+L) (HRP) |
|
43R-1650 |
Fitzgerald |
1 ml |
EUR 813 |
|
|
|
Description: Strongzyme Rabbit anti Goat IgG (H + L) (HRP) secondary antibody |
 (HRP)) Strongzyme Goat anti Rabbit IgG (H + L) (HRP) |
|
43R-1652 |
Fitzgerald |
1 ml |
EUR 648 |
|
|
|
Description: Strongzyme Goat anti Rabbit IgG (H + L) secondary antibody (HRP) |
 genesig Easy kit for Strongylus vulgaris |
|
Z-Path-S.vulgaris-EASY |
Novacyt Group |
50 tests |
EUR 410 |
|
Description: S.vulgaris |
 ELISA Kit (Human) (OKNA00174)) Strongyloides (IgG/IgM) ELISA Kit (Human) (OKNA00174) |
|
OKNA00174 |
Aviva Systems Biology |
96 Wells |
EUR 505.2 |
|
Description: Description of target: Strongyloides is a genus containing some 50 species of obligate gastrointestinal parasites of vertebrates. Strongyloides stercoralis is the scientific name of a human parasitic roundworm causing the disease of strongyloidiasis. Its common name is pinworm in the UK and threadworm in the US. The Strongyloides stercoralis nematode can parasitize humans. The adult parasitic stage lives in tunnels in the mucosa of the small intestine.S. stercoralis can be found in areas with tropical and subtropical climates but cases also occur in temperate area, more frequently in rural areas. S. stercoralis has a very low prevalence in societies where fecal contamination of soil or water is rare. Many people infected are usually asymptomatic at first. Symptoms include dermatitis: swelling, itching, larva currens, and mild hemorrhage at the site where the skin has been penetrated. If the parasite reaches the lungs, the chest may feel as if it is burning, and wheezing and coughing may result, along with pneumonia-like symptoms (Löffler's syndrome). The intestines could eventually be invaded, leading to burning pain, tissue damage, sepsis, and ulcers. In severe cases, edema may result in obstruction of the intestinal tract, as well as loss of peristaltic contractions. Strongyloides infection in immunocompromised individuals (particularly following the administration of steroids, for example following transplant surgery) can result in disseminated strongyloidiasis, in which worms move beyond the confines of the gut into other organs. This is fatal unless antiStrongyloides therapy is given.Locating juvenile larvae, either rhabditiform or filariform, in recent stool samples will confirm the presence of this parasite. Other techniques used include direct fecal smears, culturing fecal samples on agar plates, serodiagnosis through ELISA, and duodenal fumigation.;Species reactivity: Human;Application: ;Assay info: Assay Methodology: Quantitative Reverse Capture Sandwich ELISA ;Sensitivity: Sensitivity is determined as the probability of the assay indicating a positive score in samples with the specific analyte present: 87.9% |
) StrongZyme Streptavidin-PolyHRP (High Load) |
|
43R-1645 |
Fitzgerald |
1 mg |
EUR 380 |
|
|
|
Description: StrongZyme Streptavidin-PolyHRP conjugate (High Load) |
 ELISA Kit) Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-10x96StripWells |
MyBiosource |
10x96-Strip-Wells |
EUR 6725 |
Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-48StripWells |
MyBiosource |
48-Strip-Wells |
EUR 550 |
Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-5x96StripWells |
MyBiosource |
5x96-Strip-Wells |
EUR 3420 |
Rat Strongyloides Stercoralis Antibody (SS-IgM) ELISA Kit |
|
MBS9392751-96StripWells |
MyBiosource |
96-Strip-Wells |
EUR 765 |
 genesig Real-time PCR detection kit for Strongylus vulgaris |
|
Z-Path-S-vulgaris |
Novacyt Group |
150 tests |
EUR 808 |
|
Description: S.vulgaris |
 genesig Std Real-time PCR detection kit, Strongylus vulgaris |
|
Z-Path-S-vulgaris-std |
Novacyt Group |
150 tests |
EUR 602 |
|
|
|
Description: S.vulgaris |
Longitudinal Hyperlinks between Adolescent and Peer Conduct Issues and Moderation by a Sensitivity Genetic Index
Essentially the most extensively studied affect on adolescent conduct downside behaviors is friends, and the literature factors to genetics as one supply of particular person variations in peer affect. The aim of this research was to check the speculation that an environmental sensitivity genetic index comprised of DRD4, 5-HTTLPR, and GABRA2 variation would reasonable the affiliation between peer and adolescent conduct issues.
Latent development modeling was utilized to PROSPER challenge longitudinal knowledge from adolescents and their friends. Outcomes confirmed the speculation was supported; adolescents with extra copies of putative sensitivity alleles have been extra strongly influenced by their friends. The interplay kind was according to differential susceptibility in follow-up analyses. Strengths and weaknesses of genetic aggregates for sensitivity analysis are mentioned.
The use and misuse of regression fashions in panorama genetic analyses
The sphere of panorama genetics has been quickly evolving, adopting and adapting analytical frameworks to handle analysis questions. Present research are more and more utilizing regression-based frameworks to deduce the person contributions of panorama and habitat variables on genetic differentiation.
This paper outlines acceptable and inappropriate makes use of of a number of regression for these functions, and demonstrates by means of simulation the restrictions of various analytical frameworks for making appropriate inference. Of explicit concern are latest research looking for to elucidate genetic variations by becoming regression fashions with efficient distance variables calculated independently on separate panorama resistance surfaces. When transferring throughout the panorama, organisms can’t reply independently and uniquely to habitat and panorama options.
Analyses looking for to know how panorama options have an effect on gene circulate ought to mannequin a single conductance or resistance floor as a parameterized perform of related spatial covariates, and estimate the values of those parameters by linking a single set of resistance distances to noticed genetic dissimilarity by way of a loss perform.
Whereas this loss perform might contain a regression-like step, the related nuisance parameters usually are not interpretable when it comes to organismal motion and shouldn’t be conflated with what is definitely of curiosity: the mapping between spatial covariates and conductance/resistance.
The expansion and evolution of panorama genetics as a area has been fast and thrilling. It’s the aim of this paper to focus on previous missteps and exhibit limitations of present approaches to make sure that future use of regression fashions will appropriately contemplate the method being modeled, which is able to present readability to mannequin interpretation.
Affiliation analysis of the surfactant protein-C gene to childhood bronchial bronchial asthma
Targets: This analysis objectives to elucidate the molecular variability throughout the SFTPC gene in a childhood persistent respiratory sickness, bronchial bronchial asthma, throughout the Tunisian inhabitants and to determine the implications based totally on a case-control analysis of p.Thr138Asn (T138N) and p.Ser186Asn (S186N) variants.
Methods: We used direct sequencing for the genotyping of the SFTPC gene inside 101 asthmatic children. The analysis of T138N and S186N variants in 110 controls is carried out by the PCR-RFLP technique. Outcomes: The molecular analysis revealed 26 variants along with 24 intronic variations and a pair of exonic variations (T138N and S186N) with respective frequencies of 16.8% and 18.3%. We carried out a case-control analysis of the two acknowledged exonic
variations. A particular genotypic and allelic distribution between the two groups was well-known. Solely the T138N polymorphism confirmed a serious affiliation with bronchial bronchial asthma sickness (p < 10-3).
Statistical analysis elaborated Four haplotypes with the following frequencies in victims vs controls: 138Thr-186Ser (79.5% vs 57.6%), 138Thr-186Asn (3.7% vs 7.8%), 138Asn-186Thr (2.2% vs 20.2%) and 138Asn-186Asn (14.6% vs 14.4%). A serious distinction (p < 10-3) was highlighted in haplotype distribution. The 138Asn-186Ser (OR [95%CI] = 0.14[0.04-0.54], p = 0.004, R2=0.93) and 138Thr-186Asn (OR [95%CI] = 0.35[0.12-0.54], p = 0.047, R2=0.88) haplotypes confirmed a harmful affiliation with bronchial bronchial asthma which may symbolize a defending difficulty in opposition to the sickness.
Conclusion: In Tunisia, this work constitutes the first report throughout the SFTPC gene and highlights the genetic variability of the SFTPC gene in bronchial bronchial asthma. As a consequence of this truth, the case-controls analysis is also useful throughout the analysis of surfactant proteins dysfunction in persistent respiratory sickness at an early age.
 Enzalutamide-d6 |
|
HY-70002S1 |
MedChemExpress |
1 mg |
EUR 811.7 |
|
Description: Enzalutamide-d6 is a deuterium labeled Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells[1]. |
 Enzalutamide-d3 |
|
T11208-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Enzalutamide-d3 |
Enzalutamide-d3 |
|
T11208-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Enzalutamide-d3 |
) MDV3100 (Enzalutamide) |
|
A3003-10 |
ApexBio |
10 mg |
EUR 40 |
|
|
|
Description: Endocrinology and Hormones|Androgen Receptor |
MDV3100 (Enzalutamide) |
|
A3003-25 |
ApexBio |
25 mg |
EUR 182.4 |
|
|
|
Description: Endocrinology and Hormones|Androgen Receptor |
MDV3100 (Enzalutamide) |
|
A3003-5 |
ApexBio |
5 mg |
EUR 72 |
|
|
|
Description: Endocrinology and Hormones|Androgen Receptor |
MDV3100 (Enzalutamide) |
|
A3003-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 68 |
|
|
|
Description: Endocrinology and Hormones|Androgen Receptor |
MDV3100 (Enzalutamide) |
|
A3003-50 |
ApexBio |
50 mg |
EUR 104 |
|
|
|
Description: Endocrinology and Hormones|Androgen Receptor |
MDV3100 (Enzalutamide) |
|
A3003-S |
ApexBio |
Evaluation Sample |
EUR 24 |
|
|
|
Description: Endocrinology and Hormones|Androgen Receptor |
 MDV3100 Enzalutamide |
|
MBS132079-100mg |
MyBiosource |
100mg |
EUR 1065 |
MDV3100 Enzalutamide |
|
MBS132079-500mg |
MyBiosource |
500mg |
EUR 2775 |
) Enzalutamide (MDV3100) |
|
MBS578579-10mg |
MyBiosource |
10mg |
EUR 150 |
Enzalutamide (MDV3100) |
|
MBS578579-25mg |
MyBiosource |
25mg |
EUR 155 |
Enzalutamide (MDV3100) |
|
MBS578579-2mg |
MyBiosource |
2mg |
EUR 120 |
Enzalutamide (MDV3100) |
|
MBS578579-50mg |
MyBiosource |
50mg |
EUR 180 |
Enzalutamide (MDV3100) |
|
MBS578579-5mg |
MyBiosource |
5mg |
EUR 145 |
 N-desmethyl Enzalutamide |
|
HY-70002A |
MedChemExpress |
100mg |
EUR 606.07 |
|
Description: N-desmethyl Enzalutamide is the active metabolite of Enzalutamide.N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1]. |
N-desmethyl Enzalutamide |
|
MBS3600977-10mg |
MyBiosource |
10mg |
EUR 260 |
N-desmethyl Enzalutamide |
|
MBS3600977-50mg |
MyBiosource |
50mg |
EUR 575 |
N-desmethyl Enzalutamide |
|
MBS3600977-5x50mg |
MyBiosource |
5x50mg |
EUR 2260 |
 N-desMethyl EnzalutaMide |
|
MBS3840124-10mg |
MyBiosource |
10mg |
EUR 220 |
N-desMethyl EnzalutaMide |
|
MBS3840124-25mg |
MyBiosource |
25mg |
EUR 360 |
N-desMethyl EnzalutaMide |
|
MBS3840124-50mg |
MyBiosource |
50mg |
EUR 580 |
N-desMethyl EnzalutaMide |
|
MBS3840124-5x50mg |
MyBiosource |
5x50mg |
EUR 2600 |
N-desmethyl Enzalutamide |
|
MBS5756064-100mg |
MyBiosource |
100mg |
EUR 775 |
N-desmethyl Enzalutamide |
|
MBS5756064-10mg |
MyBiosource |
10mg |
EUR 190 |
N-desmethyl Enzalutamide |
|
MBS5756064-2mg |
MyBiosource |
2mg |
EUR 150 |
N-desmethyl Enzalutamide |
|
MBS5756064-50mg |
MyBiosource |
50mg |
EUR 465 |
N-desmethyl Enzalutamide |
|
MBS5756064-5mg |
MyBiosource |
5mg |
EUR 170 |
N-desmethyl Enzalutamide |
|
T19450-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide |
N-desmethyl Enzalutamide |
|
T19450-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide |
N-desmethyl Enzalutamide |
|
T19450-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide |
N-desmethyl Enzalutamide |
|
T19450-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide |
N-desmethyl Enzalutamide |
|
T19450-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide |
 Enzalutamide carboxylic acid |
|
HY-70002B |
MedChemExpress |
1 mg |
EUR 606.07 |
|
Description: Enzalutamide carboxylic acid (MDV3100 carboxylic acid) is an inactive metabolite of Enzalutamide (MDV3100). Enzalutamide is an androgen receptor (AR) antagonist[1]. |
Enzalutamide carboxylic acid |
|
MBS3611549-10mg |
MyBiosource |
10mg |
EUR 375 |
Enzalutamide carboxylic acid |
|
MBS3611549-25mg |
MyBiosource |
25mg |
EUR 475 |
Enzalutamide carboxylic acid |
|
MBS3611549-2mg |
MyBiosource |
2mg |
EUR 245 |
Enzalutamide carboxylic acid |
|
MBS3611549-50mg |
MyBiosource |
50mg |
EUR 650 |
Enzalutamide carboxylic acid |
|
MBS3611549-5mg |
MyBiosource |
5mg |
EUR 315 |
Enzalutamide carboxylic acid |
|
MBS5759031-10mg |
MyBiosource |
10mg |
EUR 275 |
Enzalutamide carboxylic acid |
|
MBS5759031-1mg |
MyBiosource |
1mg |
EUR 150 |
Enzalutamide carboxylic acid |
|
MBS5759031-25mg |
MyBiosource |
25mg |
EUR 390 |
Enzalutamide carboxylic acid |
|
MBS5759031-2mg |
MyBiosource |
2mg |
EUR 175 |
Enzalutamide carboxylic acid |
|
MBS5759031-5mg |
MyBiosource |
5mg |
EUR 215 |
Enzalutamide carboxylic acid |
|
T8217-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid |
Enzalutamide carboxylic acid |
|
T8217-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid |
Enzalutamide carboxylic acid |
|
T8217-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid |
Enzalutamide carboxylic acid |
|
T8217-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid |
Enzalutamide carboxylic acid |
|
T8217-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid |
 N-desmethyl Enzalutamide D6 |
|
T19449-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide D6 |
N-desmethyl Enzalutamide D6 |
|
T19449-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide D6 |
N-desmethyl Enzalutamide D6 |
|
T19449-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide D6 |
N-desmethyl Enzalutamide D6 |
|
T19449-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide D6 |
N-desmethyl Enzalutamide D6 |
|
T19449-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: N-desmethyl Enzalutamide D6 |
 N-desmethyl Enzalutamide-d6 |
|
HY-70002AS |
MedChemExpress |
1 mg |
EUR 811.7 |
|
Description: N-desmethyl Enzalutamide-d6 is a deuterium labeled N-desmethyl Enzalutamide. N-desmethyl Enzalutamide is an active metabolite of Enzalutamide. N-desmethyl Enzalutamide is the active metabolite of Enzalutamide. N-desmethyl Enzalutamide demonstrates primary and secondary pharmacodynamics of similar potency to Enzalutamide and circulates at approximately the same plasma concentrations as enzalutamide[1]. |
 Enzalutamide carboxylic acid D6 |
|
T19311-10mg |
TargetMol Chemicals |
10mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid D6 |
Enzalutamide carboxylic acid D6 |
|
T19311-1g |
TargetMol Chemicals |
1g |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid D6 |
Enzalutamide carboxylic acid D6 |
|
T19311-1mg |
TargetMol Chemicals |
1mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid D6 |
Enzalutamide carboxylic acid D6 |
|
T19311-50mg |
TargetMol Chemicals |
50mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid D6 |
Enzalutamide carboxylic acid D6 |
|
T19311-5mg |
TargetMol Chemicals |
5mg |
Ask for price |
|
|
|
Description: Enzalutamide carboxylic acid D6 |
 Enzalutamide carboxylic acid-d6 |
|
HY-70002BS |
MedChemExpress |
5 mg |
EUR 1011.92 |
|
Description: Enzalutamide carboxylic acid-d6 is the deuterium labeled Enzalutamide carboxylic acid (MDV3100 carboxylic acid). Enzalutamide carboxylic acid is an inactive metabolite of Enzalutamide[1]. |
Ripa lysate (strong) |
|
E1WP106 |
EnoGene |
50ML |
EUR 60 |
RIPA Lysis Buffer (Strong) |
|
abx090624-100l |
Abbexa |
100 µl |
EUR 150 |
RIPA Lysis Buffer (Strong) |
|
abx090624-100ml |
Abbexa |
100 ml |
EUR 260.4 |
|
|
RIPA Lysis Buffer (Strong) |
|
abx090624-1ml |
Abbexa |
1 ml |
Ask for price |
RIPA Lysis Buffer (Strong) |
|
abx090624-200l |
Abbexa |
200 µl |
Ask for price |
RIPA Lysis Buffer (Strong) |
|
MBS355478-100mL |
MyBiosource |
100mL |
EUR 210 |
RIPA Lysis Buffer (Strong) |
|
MBS355478-5x100mL |
MyBiosource |
5x100mL |
EUR 640 |
Carbol Fuchsin (ZN,Strong) |
|
S005-125ML |
EWC Diagnostics |
1 unit |
EUR 3.16 |
|
Description: Carbol Fuchsin (ZN,Strong) |
Carbol Fuchsin (ZN,Strong) |
|
S005-500ML |
EWC Diagnostics |
1 unit |
EUR 10.92 |
|
Description: Carbol Fuchsin (ZN,Strong) |
Clear Seal Strong Sheet (100) |
|
MAAB-0685 |
Westburg |
each |
EUR 255.61 |
HiDecal (Strong decalcifying solution) |
|
R085-500ML |
EWC Diagnostics |
1 unit |
EUR 21.95 |
|
Description: HiDecal (Strong decalcifying solution) |
Tissue/cell lysis buffer（Strong) |
|
RM17482 |
Abclonal |
10mL |
EUR 53.14 |
Modified Duncan Strong (DS) Medium |
|
M1237-500G |
EWC Diagnostics |
1 unit |
EUR 80.55 |
|
Description: Modified Duncan Strong (DS) Medium |
Tags:
dna ancestry,
dna bts,
dna definition,
dna extraction,
dna gacha life,
dna h&r block,
dna hrblock login,
dna lyrics,
dna molecule,
dna nucleotide,
dna painter,
dna polymerase,
dna productions,
dna replication,
dna strand,
dna structure,
dna synthesis,
dna testing,
dna testing kits,
dna.hrblock.com,
dnajlion7 youtube,
dnalion7 youtube,
rna bases,
rna binder,
rna binder crossword,
rna definition,
rna interference,
rna meaning,
rna molecules,
rna polymerase,
rna primase,
rna primer,
rna processing,
rna reset,
rna sequencing,
rna sugar,
rna virus,
rna vs dna,
rna world,
rna-seq,
rnai,
rnascope,
rnase,
rnation.riteaid.com
